| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $58M |
Buys | $49,999,998 | 2 | 17 |
Sells | $75,234 | 10 | 83 |
| COLUMN GROUP III GP, LP | 10 percent owner | 1 | $25M | 0 | $0 | $25M |
| GOEDDEL DAVID V | 1 | $25M | 0 | $0 | $25M | |
| Higa Tomohiro | SVP, Finance | 0 | $0 | 2 | $1,952 | $-1,952 |
| Saito Chihiro | SVP, Accounting and Fin. Ops. | 0 | $0 | 2 | $11,627 | $-11,627 |
| Tingley Whittemore | Chief Medical Officer | 0 | $0 | 3 | $26,784 | $-26,784 |
| Ali Faraz | Chief Executive Officer | 0 | $0 | 3 | $34,872 | $-34,872 |
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Over the last 12 months, insiders at Tenaya Therapeutics, Inc. have bought $50M and sold $75,234 worth of Tenaya Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Tenaya Therapeutics, Inc. have bought $40.42M and sold $128,606 worth of stock each year.
Highest buying activity among insiders over the last 12 months: COLUMN GROUP III GP, LP (10 percent owner) — $25M. GOEDDEL DAVID V () — $25M.
The last purchase of 35,714,284 shares for transaction amount of $25M was made by GOEDDEL DAVID V () on 2025‑03‑05.
| 2025-05-16 | Sale | Ali Faraz | Chief Executive Officer | 3,189 0.0019% | $0.44 | $1,412 | +5.05% | |
| 2025-05-16 | Sale | Tingley Whittemore | Chief Medical Officer | 2,937 0.0018% | $0.44 | $1,300 | +5.05% | |
| 2025-05-16 | Sale | Higa Tomohiro | SVP, Finance | 1,390 0.0008% | $0.44 | $615 | +5.05% | |
| 2025-03-10 | Sale | Ali Faraz | Chief Executive Officer | 9,741 0.0067% | $0.54 | $5,245 | -4.33% | |
| 2025-03-10 | Sale | Tingley Whittemore | Chief Medical Officer | 7,398 0.0051% | $0.54 | $3,983 | -4.33% | |
| 2025-03-10 | Sale | Higa Tomohiro | SVP, Finance | 2,482 0.0017% | $0.54 | $1,336 | -4.33% | |
| 2025-03-05 | GOEDDEL DAVID V | 35.71M 63.7654% | $0.70 | $25M | +6.24% | |||
| 2025-03-05 | COLUMN GROUP III GP, LP | 10 percent owner | 35.71M 63.7654% | $0.70 | $25M | +6.24% | ||
| 2024-11-18 | Sale | Saito Chihiro | SVP, Accounting and Fin. Ops. | 2,258 0.0029% | $2.12 | $4,787 | -53.18% | |
| 2024-08-16 | Sale | Ali Faraz | Chief Executive Officer | 9,748 0.0131% | $2.89 | $28,216 | -50.17% | |
| 2024-08-16 | Sale | Tingley Whittemore | Chief Medical Officer | 7,428 0.01% | $2.89 | $21,500 | -50.17% | |
| 2024-08-16 | Sale | Saito Chihiro | SVP, Accounting and Fin. Ops. | 2,363 0.0032% | $2.89 | $6,840 | -50.17% | |
| 2024-03-05 | Sale | Hoey Timothy | Chief Scientific Officer | 3,300 0.0044% | $7.00 | $23,101 | -58.82% | |
| 2024-02-20 | Sale | Hoey Timothy | Chief Scientific Officer | 6,569 0.0087% | $5.34 | $35,046 | -44.47% | |
| 2024-02-16 | Sale | Hoey Timothy | Chief Scientific Officer | 4,681 0.0064% | $5.86 | $27,431 | -53.48% | |
| 2024-02-16 | Sale | Ali Faraz | Chief Executive Officer | 6,358 0.0087% | $5.86 | $37,258 | -53.48% | |
| 2024-02-16 | Sale | Tingley Whittemore | Chief Medical Officer | 6,500 0.0088% | $5.86 | $38,090 | -53.48% | |
| 2024-02-16 | Sale | PATTERSON LEONE D | Chief Fin. and Bus. Officer | 5,201 0.0071% | $5.86 | $30,478 | -53.48% | |
| 2024-02-12 | GOEDDEL DAVID V | 2.22M 2.6767% | $4.50 | $10M | -47.35% | |||
| 2024-02-12 | COLUMN GROUP III GP, LP | 10 percent owner | 2.22M 2.6767% | $4.50 | $10M | -47.35% |
| GOEDDEL DAVID V | 49313559 30.3157% | $21.22M | 8 | 0 | +17.53% | |
| COLUMN GROUP III GP, LP | 10 percent owner | 49313559 30.3157% | $21.22M | 8 | 0 | +17.53% |
| Ali Faraz | Chief Executive Officer | 317325 0.1951% | $136,576.68 | 0 | 5 | |
| Tingley Whittemore | Chief Medical Officer | 171856 0.1056% | $73,966.82 | 0 | 5 | |
| Higa Tomohiro | SVP, Finance | 98300 0.0604% | $42,308.32 | 0 | 2 | |
| Saito Chihiro | SVP, Accounting and Fin. Ops. | 60983 0.0375% | $26,247.08 | 0 | 2 | |
| Casdin Eli | director | 6078860 3.737% | $2.62M | 2 | 0 | <0.0001% |
| Casdin Partners Master Fund, L.P. | 10 percent owner | 3224849 1.9825% | $1.39M | 1 | 0 | <0.0001% |
| Srivastava Deepak | director | 372435 0.229% | $160,296.02 | 1 | 0 | +31.33% |
| Hoey Timothy | Chief Scientific Officer | 245346 0.1508% | $105,596.92 | 0 | 6 | |
| PATTERSON LEONE D | Chief Fin. and Bus. Officer | 60755 0.0373% | $26,148.95 | 0 | 2 |
$2,600,095 | 110 | 13.50% | $73.07M | |
$992,222,850 | 90 | -12.52% | $72.22M | |
$4,898,715 | 46 | 40.75% | $72.25M | |
$332,528,129 | 45 | 28.82% | $75.14M | |
$671,363 | 44 | -16.23% | $67.36M | |
$22,288,598 | 37 | 25.99% | $67.06M | |
$1,602,584 | 20 | 15.26% | $69.16M | |
$26,736,140 | 20 | -18.64% | $72.22M | |
Tenaya Therapeutics, Inc. (TNYA) | $111,692,551 | 18 | 13.51% | $70.01M |
$14,562,799 | 14 | -4.77% | $75.02M | |
$17,567,343 | 12 | 34.87% | $76.2M | |
$15,724,108 | 9 | 124.63% | $71.66M | |
$4,895,542 | 8 | -11.85% | $63.43M | |
$91,549,696 | 8 | -6.55% | $68.41M | |
$4,745,999 | 5 | -4.91% | $63.11M | |
$18,186,879 | 4 | 49.41% | $69.56M | |
$6,049,986 | 4 | -8.38% | $68.2M | |
$4,256,958 | 4 | 22.95% | $70.72M | |
$19,175,155 | 2 | 40.00% | $66.98M |
| Increased Positions | 53 | +49.07% | 11M | +25.16% |
| Decreased Positions | 44 | -40.74% | 6M | -13.71% |
| New Positions | 32 | New | 3M | New |
| Sold Out Positions | 13 | Sold Out | 770,074 | Sold Out |
| Total Postitions | 117 | +8.33% | 49M | +11.45% |
| Column Group Llc | $4,888.00 | 5.77% | 9.4M | 0 | 0% | 2024-12-31 |
| Casdin Capital, Llc | $3,501.00 | 4.13% | 6.73M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $2,733.00 | 3.23% | 5.26M | -39,874 | -0.75% | 2025-03-31 |
| Jpmorgan Chase & Co | $2,681.00 | 3.16% | 5.16M | +5M | +20,670.27% | 2024-12-31 |
| Vanguard Group Inc | $1,701.00 | 2.01% | 3.27M | +58,877 | +1.83% | 2024-12-31 |
| Vr Adviser, Llc | $809.00 | 0.95% | 1.56M | 0 | 0% | 2024-12-31 |
| Ghost Tree Capital, Llc | $780.00 | 0.92% | 1.5M | +150,000 | +11.11% | 2024-09-30 |
| Morgan Stanley | $774.00 | 0.91% | 1.49M | +1M | +375.51% | 2024-12-31 |
| Geode Capital Management, Llc | $660.00 | 0.78% | 1.27M | -27,419 | -2.12% | 2024-12-31 |
| State Street Corp | $574.00 | 0.68% | 1.1M | +44,194 | +4.17% | 2024-12-31 |